Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -136.52% is 78% below its 5-year average of -76.74%, near the low end of its 5-year range (-136.52%–-30.83%).
30.60% below its 12-month average of -104.53%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.17%.
RETURN ON ASSETS (ROA)
-136.52%
RETURN ON ASSETS (ROA) AVG TTM
-104.53%
RETURN ON ASSETS (ROA) AVG 3Y
-92.09%
RETURN ON ASSETS (ROA) AVG 5Y
-76.74%
RETURN ON ASSETS (ROA) AVG 10Y
-65.50%
RETURN ON ASSETS (ROA) AVG 15Y
-57.67%
RETURN ON ASSETS (ROA) AVG 20Y
-52.47%
CURRENT VS TTM AVG
-30.60%
CURRENT VS 3Y AVG
-48.24%
CURRENT VS 5Y AVG
-77.90%
CURRENT VS 10Y AVG
-108.42%
CURRENT VS 15Y AVG
-136.74%
CURRENT VS 20Y AVG
-160.18%
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-333.74%
vs the sector median at left
Inovio Pharmaceuticals, Inc.
Market Cap
$78.76M
Return on Assets (ROA)
-136.52%
TTM Avg
-104.53%
3Y Avg
-92.09%
5Y Avg
-76.74%
Market Cap
$79.04M
Return on Assets (ROA)
-41.09%
TTM Avg
-24.80%
3Y Avg
-25.41%
5Y Avg
-25.41%
Market Cap
$78.35M
Return on Assets (ROA)
-41.94%
TTM Avg
-38.20%
3Y Avg
-35.26%
5Y Avg
-28.99%
Market Cap
$78.05M
Return on Assets (ROA)
-902.18%
TTM Avg
-2200.93%
3Y Avg
-2200.93%
5Y Avg
-2200.93%
Market Cap
$79.87M
Return on Assets (ROA)
-110.64%
TTM Avg
-124.68%
3Y Avg
-93.30%
5Y Avg
-78.61%
Market Cap
$77.19M
Return on Assets (ROA)
-55.32%
TTM Avg
-66.75%
3Y Avg
-58.76%
5Y Avg
-49.95%
Market Cap
$77.15M
Return on Assets (ROA)
-38.31%
TTM Avg
-38.33%
3Y Avg
-38.15%
5Y Avg
-51.76%
Market Cap
$76.19M
Return on Assets (ROA)
-30.65%
TTM Avg
-38.63%
3Y Avg
-43.27%
5Y Avg
-38.60%
Market Cap
$76.14M
Return on Assets (ROA)
-5.84%
TTM Avg
-3.07%
3Y Avg
-3.13%
5Y Avg
-9.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | $78.76M | -136.52% | -104.53% | -92.09% | -76.74% |
| Citius Oncology, Inc. (CTOR)vs › | $79.04M | -41.09% | -24.80% | -25.41% | -25.41% |
| Pulmonx Corporation (LUNG)vs › | $78.35M | -41.94% | -38.20% | -35.26% | -28.99% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.05M | -902.18% | -2200.93% | -2200.93% | -2200.93% |
| Nutriband Inc. (NTRB)vs › | $79.87M | -110.64% | -124.68% | -93.30% | -78.61% |
| Hyperfine, Inc. (HYPR)vs › | $77.19M | -55.32% | -66.75% | -58.76% | -49.95% |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | -38.31% | -38.33% | -38.15% | -51.76% |
| Outset Medical, Inc. (OM)vs › | $76.19M | -30.65% | -38.63% | -43.27% | -38.60% |
| SkinHealth Systems Inc. (SKIN)vs › | $76.14M | -5.84% | -3.07% | -3.13% | -9.45% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $81.97M | -74.91% | -50.52% | -40.48% | -70.00% |
ROA
-136.5%
ROE
-1542.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -114.31% |
| 2024-12-31 | -94.75% |
| 2023-12-31 | -79.04% |
| 2022-12-31 | -80.28% |
| 2021-12-31 | -61.23% |
| 2020-12-31 | -30.83% |
| 2019-12-31 | -82.92% |
| 2018-12-31 | -73.96% |
| 2017-12-31 | -47.11% |
| 2016-12-31 | -42.45% |
| 2015-12-31 | -13.65% |
| 2014-12-31 | -27.41% |
| 2013-12-31 | -74.79% |
| 2012-12-31 | -43.57% |
| 2011-12-31 | -24.96% |
| 2010-12-31 | -31.42% |
| 2009-12-31 | -30.28% |
| 2008-12-31 | -33.26% |
| 2007-12-31 | -28.17% |
| 2006-12-31 | -34.71% |
| 2005-12-31 | -52.79% |
| 2004-12-31 | -52.37% |
| 2003-12-31 | -28.74% |
| 2002-12-31 | -110.07% |
| 2001-12-31 | -133.66% |
| 2000-12-31 | -83.58% |
| 1999-12-31 | -47.10% |
